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ABSTRACT
Introduction: Fixed-combination glaucoma
medications are commonly used to achieve
target intraocular pressure (IOP) reduction in
patients uncontrolled with monotherapy;
however, ocular discomfort associated with eye
drops can decrease adherence. This study
assessed the efficacy and tolerability of twice-
daily fixed-combination brinzolamide 1%/
timolol 0.5% (BRINZ/TIM-FC) in Latin
American patients transitioned from fixed-
combination brimonidine 0.2%/timolol 0.5%
(BRIM/TIM-FC) because of insufficient IOP
control or treatment intolerance.
Methods: This 8-week, open-label, prospective
study was conducted at six sites in Argentina,
Chile, and Mexico. Enrolled patients were aged
C18 years with open-angle glaucoma (including
primary, exfoliative, or pigment-dispersion
glaucoma) or ocular hypertension with IOP of
19–35 mmHg in C1 eye at baseline (on BRIM/
TIM-FC). Patients self-administered BRINZ/TIM-
FC to both eyes at 8 a.m. and 8 p.m. daily for
8 weeks. The primary and secondary efficacy
endpoints were mean IOP change from baseline
at week 8 and percentage of patients achieving
target IOP (B18 mmHg) at week 8, respectively.
Exploratory endpoints included patient and
investigator preference for treatment at week
8. Adverse events (AEs) were assessed as the
safety endpoint.
Results: Fifty patients (mean ± SD age,
66.7 ± 11.5 years) received BRINZ/TIM-FC, and
49 were included in the intent-to-treat
population. Mean ± SD IOP was significantly
reduced from baseline after 8 weeks of
treatment with BRINZ/TIM-FC
(-3.6 ± 3.0 mmHg; P\0.0001, Wilcoxon
signed-rank test; 17.1% reduction). Overall,
55.3% of patients achieved IOP B18 mmHg at
week 8. Significantly more patients (89.4%) and
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investigators (95.7%) preferred BRINZ/TIM-FC
to BRIM/TIM-FC (both P\0.0001, exact
binomial test). Of the 13 AEs observed, 8 were
related to BRINZ/TIM-FC; the most common
treatment-related AEs were eye irritation (n = 4)
and abnormal sensation in the eye (n = 2).
Conclusion: BRINZ/TIM-FC provides an
effective and well-tolerated treatment option
for patients transitioned from BRIM/TIM-FC.
Keywords: b-Blocker; Carbonic anhydrase
inhibitor; Fixed combination; Glaucoma;
Intraocular pressure; Latin America; Ocular
hypertension; Ophthalmology
INTRODUCTION
Glaucoma is a leading cause of blindness in
Latin America and worldwide [1]. Globally,
nearly 80 million people are projected to be
diagnosed with glaucoma in 2020, more than 8
million of whom are expected to be from Latin
America [1]. Elevated intraocular pressure (IOP)
is a major risk factor for primary open-angle
glaucoma [2]; the primary treatment approach
to slow progression of glaucoma and ocular
hypertension is reducing IOP [3]. Several topical
IOP-lowering medications exist; these include
medications that decrease aqueous humor
production and increase aqueous humor
outflow (e.g., carbonic anhydrase inhibitors, b-
blockers, a-agonists) [3]. Treatment with a
single topical agent is often insufficient to
control IOP, and many patients require an
additional IOP-lowering agent to achieve their
targets [3, 4]. Concomitant use of multiple
ocular hypotensive agents may be
inconvenient and has been associated with
increased risk of drug washout [5], decreased
adherence and persistence [6, 7], increased
exposure to preservatives and risk of
preservative-related ocular surface disease [8,
9], and potentially higher treatment costs [10].
Fixed-combination medications for
glaucoma enable treatment with multiple
mechanisms of action in a single topical
medication, providing additive IOP-lowering
efficacy without increasing treatment
complexity or introducing risk of drug
washout. The fixed-combination therapy
brinzolamide 1%/timolol 0.5% (BRINZ/TIM-
FC; Azarga; Alcon Laboratories, Inc., Fort
Worth, TX, USA) combines a carbonic
anhydrase inhibitor (CAI) with a b-blocker and
has IOP-lowering efficacy greater than the
component monotherapies [11]. Although the
safety and efficacy of BRINZ/TIM-FC have been
demonstrated in previous studies [12, 13], there
are few data on the IOP-lowering efficacy of
BRINZ/TIM-FC in patients who transitioned to
BRINZ/TIM-FC because of insufficient IOP
control or intolerance of a fixed combination
containing the a-agonist brimonidine.
Brimonidine 0.2%/timolol 0.5% fixed-
combination therapy (BRIM/TIM-FC;
Combigan; Allergan, Inc., Irvine, CA, USA)
has shown efficacy greater than brimonidine or
timolol monotherapy alone in patients with
glaucoma or ocular hypertension [14].
The objective of this study was to assess the
efficacy and tolerability of transitioning to
BRINZ/TIM-FC from prior BRIM/TIM-FC in
Latin American patients with open-angle
glaucoma or ocular hypertension.
METHODS
Study Design
This was an 8-week, multicenter, open-label
study conducted at six clinical sites in
Argentina, Chile, and Mexico from December
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2011 to February 2013 that was designed to
evaluate the tolerability and efficacy of
changing to BRINZ/TIM-FC from prior BRIM/
TIM-FC in patients with open-angle glaucoma
or ocular hypertension. The study consisted of
one screening/baseline visit and two follow-up
visits conducted after 4 and 8 weeks of
treatment. At screening/baseline, patient
diagnosis was recorded on a case report form.
The form contained a single diagnosis entry for
both eyes; in the event that qualifying
glaucoma diagnoses differed between eyes, a
diagnosis of ‘‘non-specified glaucoma’’ was
recorded. Patients received BRINZ/TIM-FC and
were instructed to self-administer one drop to
each eye twice daily (at 8 a.m. and 8 p.m.)
throughout the study. Patients were required to
discontinue any prior ocular hypotensive
therapy at screening. To represent typical
clinical practice patterns and to avoid
potentially unsafe increases in IOP, there was
no washout period between discontinuation of
prior medication and initiation of BRINZ/TIM-
FC therapy. The following assessments were
performed at baseline: best-corrected
monocular visual acuity (BCVA) assessment;
biomicroscopy of eyelids, conjunctiva, cornea,
iris, anterior chamber, and lens; confirmation of
open-angle glaucoma by gonioscopy; IOP
measurement by Goldmann applanation
tonometry; and survey-based assessment of
ocular symptoms. BCVA, biomicroscopy, and
IOP were also assessed at weeks 4 and 8. At week
8, patients completed the ocular symptom
survey, global preference response, and
adherence questionnaire; investigators
completed the global preference response for
each patient based on the patient’s IOP
response to BRINZ/TIM-FC.
The study protocol was approved by all
relevant institutional review boards or
independent ethics committees, and the study
was performed in compliance with the ethical
principles of the Declaration of Helsinki and
Good Clinical Practice. Before entering the
study, all patients provided written informed
consent. This trial is registered at
Clinicaltrials.gov, number NCT01518244.
Patients
Eligible patients were aged C18 years with an
existing diagnosis of ocular hypertension or
primary, exfoliative, or pigment-dispersion
open-angle glaucoma in C1 eye and were on
a stable BRIM/TIM-FC treatment regimen for
C30 days before screening. Other inclusion
criteria were IOP between 19 and 35 mmHg in
C1 eye while on BRIM/TIM-FC, BCVA of
20/200 (Snellen) or better in each eye, and
willingness to discontinue use of all other
ocular hypotensive agents at screening and
throughout the study. Patients must have had
IOP considered safe by the investigators in
both eyes to ensure clinical stability of vision
and the optic nerve. Key exclusion criteria
were hypersensitivity to the study medication;
presence of a primary or secondary glaucoma
other than exfoliative or pigment-dispersion
glaucoma; ocular herpes simplex; any
abnormality preventing reliable applanation
tonometry or examination of the ocular
fundus or anterior chamber; corneal
dystrophy; conjunctivitis, keratitis, or
uveitis; intraocular surgery B3 months before
screening; cardiopulmonary conditions that
precluded safe administration of a topical b-
blocker; use of systemic medications that
affect IOP without a stable course for
C7 days before screening and throughout the
study; use of corticosteroids B30 days before
screening; and risk of visual field or visual
acuity worsening as a consequence of
participation in the study.
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Efficacy Outcomes
The primary efficacy variable was change in IOP
from baseline to week 8. The percentage of
patients with IOP B18 mmHg at week 8 was the
secondary efficacy variable. IOP was assessed by
the same operator with the same tonometer at
least 2 h after the morning instillation of the
study drug and at approximately the same time
of day for all visits. Exploratory efficacy
variables were ocular symptom survey
responses by visit and change from baseline to
week 8, adherence questionnaire responses at
week 8, and patient and investigator global
preference responses at week 8. The global
preference questionnaire consisted of a single
question with a forced-choice binary response
(i.e., preferred study medication [BRINZ/TIM-
FC] or preferred prior medication [BRIM/TIM-
FC]).
Safety Outcomes
Safety was assessed by monitoring adverse event
(AE) reports. Ocular signs (evaluated by slit-
lamp biomicroscopy) and BCVA were evaluated
for each eye at all study visits.
Statistical Analysis
If only one eye was eligible for inclusion and
treatment, this eye was selected for the efficacy
analysis; if both eyes were eligible, the worse eye
(i.e., the eye with the higher IOP at baseline)
was selected. If both eyes had equal IOP at
baseline, the right eye was selected. Efficacy
outcomes were analyzed in the intent-to-treat
(ITT) population (i.e., patients who received
BRINZ/TIM-FC and had C1 on-therapy study
visit) and the per-protocol population (i.e., all
subjects who received BRINZ/TIM-FC,
completed all study visits, and satisfied all
inclusion/exclusion criteria); missing data were
not imputed. For the primary efficacy variable,
differences in IOP measurements between
baseline and week 8 were compared using
Wilcoxon signed-rank tests. To assess the
effect of time on IOP, changes in IOP across
visits were evaluated using a repeated-measures
analysis of variance. Ordinal responses from the
ocular symptom survey were converted to a
numeric scale (0 = none to 4 = severe);
differences from baseline to week 8 were
assessed using Wilcoxon signed-rank tests and
sign tests. Patient and investigator responses to
the global preference questionnaire were
assessed with exact binomial tests. Safety
analyses were performed in the safety
population (i.e., all patients who received C1
dose of BRINZ/TIM-FC). Descriptive statistics
were provided for demographic, adherence, and
safety endpoints. Statistical analyses were
performed using SAS, version 9.2 (SAS
Institute Inc., Cary, NC, USA); all statistical




Fifty patients were screened and enrolled in the
study and included in the safety population.
Open anterior chamber angle was confirmed for
all patients. Mean ± SD patient age was
66.7 ± 11.5 years (range 29–87 years); 61.2% of
patients were female, and 89.8% were Hispanic
(Table 1). Three patients discontinued because
of AEs (keratitis, bacterial conjunctivitis, and
eye irritation); one patient discontinued
between baseline and week 4 and was
excluded from the ITT analysis (n = 49), and
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two patients discontinued between weeks 4 and
8.
Efficacy
Efficacy data were similar in the ITT and per-
protocol populations; results for the ITT
population are presented. At baseline (on
BRIM/TIM-FC; n = 49), mean ± SD IOP was
21.2 ± 2.5 mmHg. Mean ± SD absolute IOP
reduction from baseline to week 8 (on BRINZ/
TIM-FC; n = 47) was -3.6 ± 3.0 mmHg
(P\0.0001); mean ± SD percent IOP change
from baseline to week 8 was -17.1 ± 13.7%.
Mean IOP decreased from baseline to week 4
(n = 49) and was maintained through week 8
(Fig. 1). At week 8, 55.3% of patients (n = 26/47)
achieved the target IOP of B18 mmHg.
The proportion of patients reporting the
symptoms described in the ocular symptom
survey decreased from baseline to week 8,
except for crusting around the eyes, which
increased from 12.2% (n = 6/49) to 27.7%
(n = 13/47; Table 2). Dry eyes; excessive
tearing; and itching of the eyes, eyelids, or the
area around the eyes were significantly
improved from baseline to week 8 (all P\0.05;
Table 2).
Most patients (89.4%, n = 42/47) preferred
BRINZ/TIM-FC to BRIM/TIM-FC (P\0.0001).
Investigators preferred BRINZ/TIM-FC to
BRIM/TIM-FC for nearly all patients (95.7%,
n = 45/47; P\0.0001).
All but 1 patient (97.9%, n = 46/47) were
very confident that they would adhere to their
preferred glaucoma medication if it was
prescribed by their doctor, compared with
61.7% (n = 29/47) who were very confident
that they would adhere to their non-preferred
medication if it was prescribed (Table 3). In
total, 87.2% (n = 41/47) of patients were very
confident they would use a prescribed
medication if it did not make their eyes burn
or sting, whereas 59.6% (n = 28/47) of patients
were very confident that they would use a
prescribed medication if it did cause such
symptoms (Table 3).
Table 1 Patient demographics (intent-to-treat
population)
Characteristic BRINZ/TIM-FC (n5 49)
Age, years








Weight, mean ± SD, kg 71.7 ± 15.3
Height, mean ± SD, cm 163.9 ± 11.1
BMI, mean ± SD, kg/m2 26.6 ± 4.7
Diagnosis, n (%)a
Open-angle glaucoma 26 (53.1)
Non-speciﬁed glaucomab 22 (44.9)
Ocular hypertension 4 (8.2)
BMI Body mass index, BRINZ/TIM-FC ﬁxed-
combination brinzolamide 1%/timolol 0.5%
a Two diagnoses were recorded for some patients, causing
the total number of diagnoses to exceed 49
b Recorded for each patient who had a single glaucoma
entry for both eyes; type of glaucoma was not allowed to be
speciﬁed for each eye. Two patients presented with
pseudoexfoliation glaucoma and were included as non-
speciﬁed glaucoma; one patient had open-angle glaucoma
in both eyes but was assigned to the non-speciﬁed
glaucoma group because of a coding error
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Safety
A total of 13 AEs were reported for 10 patients
(Table 4). Most AEs were mild or moderate in
intensity, and all resolved with or without
treatment. Eight AEs in five patients were
considered related to BRINZ/TIM-FC; the most
common treatment-related AEs were eye
irritation (n = 4) and abnormal sensation in
the eye (n = 2). There were no serious AEs.
Approximately 50% of patients showed lens
abnormalities in the slit-lamp examination in
both eyes at baseline and follow-up visits; the
most common lens abnormality was mild
nuclear opacity. Findings for cornea, iris/
anterior chamber, eyelids, and conjunctiva
were generally unchanged from baseline at
weeks 4 and 8. No marked differences in BCVA
from baseline to week 4 or week 8 were
observed.
DISCUSSION
Fixed-combination therapies for glaucoma
provide an effective and convenient
therapeutic option for patients who cannot
maintain target IOP reduction on
monotherapy alone. BRINZ/TIM-FC and BRIM/
TIM-FC each provide two ocular hypotensive
agents in a single eye drop and achieve greater
IOP reductions than their individual
components alone. Compared with
concomitant therapy with their unfixed
components, fixed-combination therapies
provide similar IOP-lowering efficacy,
decreased treatment complexity, lower risk of
drug washout, decreased preservative exposure
and preservative-related ocular discomfort, and
may reduce treatment costs [5, 8–10]. By
simplifying treatment regimens and decreasing
risk of preservative-related ocular side effects,
Fig. 1 Mean ± SD IOP throughout the study (intent-to-
treat population). Percent IOP reduction from baseline to
week 4 and week 8 is indicated inside bars; gray bars
indicate IOP with BRINZ/TIM-FC treatment.
*P\0.0001, week 8 versus baseline; Wilcoxon test. Overall
effect of time on IOP, P\0.0001; repeated-measures
analysis of variance. BRINZ/TIM-FC ﬁxed-combination
brinzolamide 1%/timolol 0.5%, IOP intraocular pressure
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fixed combinations may also promote improved
treatment adherence.
In the current study of Latin American
patients with open-angle glaucoma or ocular
hypertension, a significant reduction in IOP was
observed after patients were transitioned from
twice-daily BRIM/TIM-FC to twice-daily BRINZ/
TIM-FC; mean IOP decreased from baseline to
week 8 by 3.6 mmHg. All enrolled patients had
a minimum IOP C19 mmHg with BRIM/TIM-
FC, and more than half of patients (n = 26/47)
achieved the target IOP of B18 mmHg after
8 weeks of treatment with BRINZ/TIM-FC.
Results of the ocular symptom survey showed
that patients reported greater ocular comfort
with BRINZ/TIM-FC compared with BRIM/TIM-
Table 2 Ocular symptom survey by visit and change from baseline (intent-to-treat population)
Question Patients, n (%) Change from baseline





Mean – SD P value
Have you had dry eyes since your last visit? 17 (35.4)c 9 (19.1) -0.35 ± 1.16 \0.0486d
Have you had pain in or around your eyes when in the light
since your last visit?
16 (32.7) 11 (23.4) -0.30 ± 1.25 \0.1321d
Have you teared more than normal since your last visit? 16 (32.7) 4 (8.5) -0.34 ± 0.94 0.0097d
Did your eye drops sting or burn when you instilled them? 26 (53.1) 18 (38.3) -0.53 ± 1.54 0.2295e
Have you had crusting around your eyes since your last visit? 6 (12.2) 13 (27.7) 0.30 ± 1.28 0.1455d
Have you had itching of eyes, eyelids, or the area around
your eyes since your last visit?
19 (38.8) 8 (17.0) -0.55 ± 0.95 0.0007e
Have you had a feeling of irritation in your eyes since your
last visit?
18 (36.7) 8 (17.0) -0.37 ± 1.18 0.0509d
Have you noticed redness in your treated eyes? 11 (22.4) 10 (21.3) -0.23 ± 1.34 0.2370d
Have other people commented about redness in your
treated eyes?
15 (30.6) 8 (17.0) NA NA
How easy is it for you to instill your eye drops in your eyes?
Very difﬁcult 2 (4.1) 0 (0.0) NA NA
Difﬁcult 2 (4.1) 4 (8.5) NA NA
Easy 19 (38.8) 18 (38.3) NA NA
Very easy 26 (53.1) 25 (53.2) NA NA
NA Not applicable
a Values represent ‘‘yes’’ responses to each question, with the exception of the question ‘‘How easy is it for you to instill your
eye drops in your eyes?’’ for which responses regarding levels of ease with instillation are shown
b Values represent change from baseline to week 8 in answers on a 5-point scale of symptom severity (0 = none;
1 = minimal; 2 = mild; 3 = moderate; 4 = severe). Negative values indicate an improvement in ocular symptoms
c n = 48
d Wilcoxon test
e Sign test
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FC. Nearly 90% of patients preferred BRINZ/
TIM-FC to BRIM/TIM-FC, possibly because of
the improved tolerability and comfort reported
for BRINZ/TIM-FC; investigators preferred
BRINZ/TIM-FC for nearly all patients (95.7%).
No substantial changes in ocular signs or BCVA
were observed throughout the study, and the
safety profile of BRINZ/TIM-FC was similar to
previous reports [12, 13]. All AEs were
consistent with AEs previously reported with
topical b-blockers and CAIs.
The observed reduction in IOP with BRINZ/
TIM-FC was evident after 4 weeks of treatment
and was maintained through 8 weeks. Mean
IOP with BRINZ/TIM-FC treatment was
17.35 mmHg and 17.51 mmHg at weeks 4 and
8, respectively; at week 8, mean IOP was
reduced by 17.1% from baseline levels
(21.2 mmHg), when patients were receiving
BRIM/TIM-FC. Furthermore, whereas no
patients had IOP \19 mmHg at baseline,
55.3% of patients achieved the target IOP of
B18 mmHg after 8 weeks of BRINZ/TIM-FC
treatment. Maintaining IOP B18 mmHg has
been associated with less disease progression
and increased stability of visual fields over
several years of patient follow-up. A meta-
analysis of five studies of patients with open-
angle glaucoma found that elevated IOP was a
significant risk factor for disease progression
over 5 years; visual fields were stable in 82% of
patients with mean IOP of 13–17 mmHg
compared with only 49% of patients with
mean IOP [18 mmHg [15]. Mean IOP was
20.0 mmHg in patients with signs of disease
progression compared with 17.1 mmHg in
patients without progression [15]. Likewise,
the Advanced Glaucoma Intervention Study
comparison of surgical interventions for
glaucoma demonstrated that visual field
progression was decreased in patients who
consistently maintained IOP levels B18 mmHg
over 6 years compared with patients who had
higher IOP levels [16]. In the Canadian
Glaucoma Study, among 249 patients with
open-angle glaucoma, those with mean IOP
[17 mmHg had significantly higher cumulative
progression compared with those with mean
IOP \15 mmHg [17]; this study also found that
the risk of progression increased by 19% for
every 1-mmHg increase in mean IOP [17].
Similarly, the Early Manifest Glaucoma Trial
demonstrated that the risk of progression
decreased by *10% for every 1-mmHg
decrease in IOP from baseline at follow-up
visits [18]. This finding was further supported
by the Canadian Glaucoma Study follow-up
Table 3 Adherence questionnaire (intent-to-treat
population)
Question, n (%) Week 8 (n5 47)
How conﬁdent is the patient that he/she will use glaucoma
medication as prescribed if the doctor:
Prescribed the medication preferred in the study
Not at all conﬁdent 0
Somewhat conﬁdent 1 (2.1)
Very conﬁdent 46 (97.9)
Prescribed the medication not preferred in the study
Not at all conﬁdent 12 (25.5)
Somewhat conﬁdent 6 (12.8)
Very conﬁdent 29 (61.7)
Prescribed a medication that makes the eyes burn or sting
Not at all conﬁdent 11 (23.4)
Somewhat conﬁdent 8 (17.0)
Very conﬁdent 28 (59.6)
Prescribed a medication that does not make the eyes burn
or sting
Not at all conﬁdent 4 (8.5)
Somewhat conﬁdent 2 (4.3)
Very conﬁdent 41 (87.2)
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report, which showed that even a modest IOP
reduction in patients with glaucoma
progression significantly slowed the rate of
visual field decline [19]. In the current study,
BRINZ/TIM-FC therapy led to significant IOP
reductions from levels maintained with BRIM/
TIM-FC. This finding is consistent with the
results of a systematic review and meta-analysis
that demonstrated greater mean diurnal IOP
reduction with BRINZ/TIM-FC compared with
BRIM/TIM-FC (-8.3 mmHg versus -6.6 mmHg,
respectively; overall difference, 1.7 mmHg) [20].
The difference in IOP with BRINZ/TIM-FC
versus BRIM/TIM-FC in the current study was
of greater magnitude than was previously
reported [20]; however, the current study did
not control for potential non-compliance with
prior BRIM/TIM-FC.
The safety and tolerability profiles of BRINZ/
TIM-FC and BRIM/TIM-FC in the current study
were similar to previous reports. In a large,
multicenter, observational study of more than
14,000 patients throughout Germany who
transitioned to BRINZ/TIM-FC from prior IOP-
lowering medications, nearly 90% of patients
judged the tolerability of BRINZ/TIM-FC
positively [13]. A total of 75.9% of evaluable
patients reported a preference for BRINZ/TIM-
FC compared with 8.6% who reported a
preference for their previous therapy [13]. Of
more than 200 patients who were transitioned
from BRIM/TIM-FC to BRINZ/TIM-FC, more
patients rated BRINZ/TIM-FC tolerability
favorably (86.5%) compared with BRIM/TIM-
FC tolerability (32.1%); similar to the results of
the current study, more patients reported a
preference for BRINZ/TIM-FC (75.8%) compared
with BRIM/TIM-FC (6.6%) [13].
The open-label, single-arm design, lack of
active control, 8-week follow-up, and subjective
nature of the surveys are potential limitations of
this study. IOP was assessed and recorded by the
same operator for each patient throughout the
study, which could have introduced bias based on
the unmasked nature of the study. The single
baseline IOP assessment for determination of
patient eligibility did not allow adjustment for
potential noncompliance with BRIM/TIM-FC at
screening, and regression to the mean may have
affected study results. Inclusion of patients with
IOP considered safe for study participation may
have introduced patient selection bias. Adherence
with BRINZ/TIM-FC may have been higher
because of the effect of participation in a clinical
trial. Furthermore, the preference questionnaire
consisted of a binary choice question; therefore,
Table 4 Summary of adverse events (safety population)
Adverse events, n (%) BRINZ/TIM-
FC
(n5 50)
Patients with C1 AE 10 (20.0)
Treatment-emergent AEs:
Eye irritation 4 (8.0)
Abnormal sensation in eye 2 (4.0)
Conjunctivitis 2 (4.0)
Foreign body sensation in eyes 1 (2.0)
Keratitis 1 (2.0)
Bacterial conjunctivitis 1 (2.0)
Viral conjunctivitis 1 (2.0)
Gastroenteritis 1 (2.0)




Eye irritation 4 (8.0)
Abnormal sensation 2 (4.0)
Foreign body sensation 1 (2.0)
Keratitis 1 (2.0)
AE Adverse event, BRINZ/TIM-FC ﬁxed-combination
brinzolamide 1%/timolol 0.5%
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patients who may have had no medication
preference were prompted to choose between
BRIM/TIM-FC and BRINZ/TIM-FC. Prior
intolerance to BRIM/TIM-FC may have
introduced bias to patients’ questionnaire
responses. Future studies including a crossover
design and longer follow-up durations would
provide valuable data regarding long-term
treatment adherence, tolerability, efficacy, and
medication preference in this patient population.
CONCLUSION
In this study of patients transitioning from
BRIM/TIM-FC to BRINZ/TIM-FC because of
insufficient IOP reduction or intolerance,
BRINZ/TIM-FC significantly reduced IOP after
4 weeks of treatment and maintained IOP
reductions through 8 weeks; more than half of
the patients studied achieved target IOP (i.e.,
B18 mmHg) after 8 weeks of treatment. BRINZ/
TIM-FC was preferred by significantly more
patients and investigators and was associated
with improved tolerability compared with
BRIM/TIM-FC. These results suggest that
BRINZ/TIM-FC is an effective and well-
tolerated option for patients transitioning
from BRIM/TIM-FC.
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